ArcelorMittal SA vs GeneDx Holdings Corp — how do they compare? ArcelorMittal SA trades at $73.73 (market cap $55.96B), while GeneDx Holdings Corp trades at $81.74 (market cap $2.32B). The key difference: ArcelorMittal SA is far larger — about 24.1× GeneDx Holdings Corp's market cap, and ArcelorMittal SA pays a 0.81% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MT | WGS | |
|---|---|---|
Market Cap | $55.96B | $2.32B |
Sector | Basic Materials | Technology |
52-Week High | $75.35 | $167.51 |
52-Week Low | $32.44 | $34.51 |
Enterprise Value | $65.53B | $2.35B |
Dividend Yield | 0.81% | — |
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $73.29, up 0.1% with bullish technical signals from moving averages despite recent earnings miss. The company shows improving fundamentals with Q2 2026 revenue growth and strong cash flow generation of $4.8B from operations. Recent corporate developments include dividend payments and strategic partnerships with Microsoft, while analyst consensus remains positive with 50% buy ratings.
Outlook remains cautiously optimistic with European business recovery potential, though risks include cyclical steel demand volatility and elevated debt levels. The stock offers value with reasonable P/S (0.89) and P/B (1.01) ratios, but investors should monitor execution on second-half shipment guidance and margin pressures from input costs.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Trailing returns across standard periods
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →